Camp4 Therapeutics Corp
CAMP
Company Profile
Business description
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Contact
One Kendall Square
Building 1400 West, 3rd Floor
CambridgeMA02139
USAT: +1 617 651-8867
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
48
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
stocks
Major ASX miner remains overvalued following production update
Iron ore strength keeps production on track despite lower copper output.
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
From Google Cloud to Gemini user retention, here’s what we expect from Alphabet’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.90 | 33.40 | 0.37% |
| CAC 40 | 8,349.80 | 9.69 | 0.12% |
| DAX 40 | 24,971.30 | 124.61 | 0.50% |
| Dow JONES (US) | 52,185.65 | 346.39 | 0.67% |
| FTSE 100 | 10,572.24 | 47.48 | 0.45% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,824.70 | 316.63 | 1.24% |
| Nikkei 225 | 66,232.19 | 2,091.07 | 3.26% |
| NZX 50 Index | 13,656.03 | 40.00 | -0.29% |
| S&P 500 | 7,499.35 | 56.07 | 0.75% |
| S&P/ASX 200 | 8,793.30 | 36.30 | 0.41% |
| SSE Composite Index | 3,864.37 | 68.09 | 1.79% |